News | February 07, 2026
Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
Hologic has been at the forefront of cervical cancer screening for decades
Hologic has been at the forefront of cervical cancer screening for decades
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The decision is based on the phase 3 DESTINY-Breast11 trial
Subscribe To Our Newsletter & Stay Updated
